Cue Biopharma, Inc.
CUE
$0.56
-$0.01-1.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -25.51% | -0.11% | 13.83% | 69.16% | 149.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -25.51% | -0.11% | 13.83% | 69.16% | 149.53% |
| Cost of Revenue | -22.04% | -36.83% | -34.68% | -30.94% | -10.81% |
| Gross Profit | 20.63% | 46.07% | 44.31% | 45.79% | 29.24% |
| SG&A Expenses | 9.32% | -7.99% | -13.32% | -7.97% | -27.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.06% | -15.38% | -15.58% | -11.49% | -3.25% |
| Operating Income | 16.50% | 18.01% | 19.61% | 20.00% | 14.22% |
| Income Before Tax | 15.53% | 17.17% | 18.78% | 19.83% | 14.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.53% | 17.17% | 18.78% | 19.83% | 14.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.53% | 17.17% | 18.78% | 19.83% | 14.03% |
| EBIT | 16.50% | 18.01% | 19.61% | 20.00% | 14.22% |
| EBITDA | 16.58% | 18.09% | 19.64% | 19.91% | 13.95% |
| EPS Basic | 49.70% | 43.46% | 37.64% | 32.50% | 24.36% |
| Normalized Basic EPS | 49.69% | 43.09% | 37.27% | 32.13% | 24.52% |
| EPS Diluted | 49.70% | 43.46% | 37.64% | 32.50% | 24.36% |
| Normalized Diluted EPS | 49.69% | 43.09% | 37.27% | 32.13% | 24.52% |
| Average Basic Shares Outstanding | 74.09% | 52.79% | 33.05% | 23.01% | 13.19% |
| Average Diluted Shares Outstanding | 74.09% | 52.79% | 33.05% | 23.01% | 13.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |